UBS AM’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.09M | Buy |
142,368
+5,343
| +4% | +$237K | ﹤0.01% | 1368 |
|
|
2026
Q1 | $4.07M | Sell |
137,025
-78,926
| -37% | -$2.36M | ﹤0.01% | 1671 |
|
|
2025
Q4 | $8.25M | Buy |
215,951
+70,024
| +48% | +$2.28M | ﹤0.01% | 1211 |
|
|
2025
Q3 | $3.49M | Sell |
145,927
-299,630
| -67% | -$5.63M | ﹤0.01% | 1534 |
|
|
2025
Q2 | $6.59M | Buy |
445,557
+378,960
| +569% | +$6.28M | ﹤0.01% | 1570 |
|
|
2025
Q1 | $1.19M | Sell |
66,597
-95,006
| -59% | -$1.93M | ﹤0.01% | 2230 |
|
|
2024
Q4 | $2.82M | Sell |
161,603
-1,572
| -1% | -$27.8K | ﹤0.01% | 1883 |
|
|
2024
Q3 | $2.28M | Sell |
163,175
-15,574
| -9% | -$162K | ﹤0.01% | 1972 |
|
|
2024
Q2 | $1.47M | Buy |
178,749
+74,769
| +72% | +$504K | ﹤0.01% | 2161 |
|
|
2024
Q1 | $802K | Buy |
103,980
+4,555
| +5% | +$38.4K | ﹤0.01% | 2115 |
|
|
2023
Q4 | $894K | Hold |
99,425
| – | – | ﹤0.01% | 2094 |
|
|
2023
Q3 | $889K | Buy |
99,425
+10,880
| +12% | +$154K | ﹤0.01% | 2020 |
|
|
2023
Q2 | $1.99M | Hold |
88,545
| – | – | ﹤0.01% | 1644 |
|
|
2023
Q1 | $1.99M | Buy |
88,545
+24,967
| +39% | +$531K | ﹤0.01% | 1644 |
|
|
2022
Q4 | $1.34M | Buy |
63,578
+1,152
| +2% | +$24.4K | ﹤0.01% | 1713 |
|
|
2022
Q3 | $1.54M | Sell |
62,426
-3,739
| -6% | -$96.6K | ﹤0.01% | 1733 |
|
|
2022
Q2 | $1.6M | Sell |
66,165
-1,016
| -2% | -$25.6K | ﹤0.01% | 1720 |
|
|
2022
Q1 | $1.73M | Buy |
67,181
+3,993
| +6% | +$106K | ﹤0.01% | 1865 |
|
|
2021
Q4 | $1.96M | Buy |
63,188
+11,413
| +22% | +$321K | ﹤0.01% | 1882 |
|
|
2021
Q3 | $1.26M | Sell |
51,775
-1,779
| -3% | -$32.7K | ﹤0.01% | 2043 |
|
|
2021
Q2 | $781K | Buy |
53,554
+4,169
| +8% | +$82.2K | ﹤0.01% | 2340 |
|
|
2021
Q1 | $1.23M | Buy |
49,385
+10,700
| +28% | +$296K | ﹤0.01% | 1991 |
|
|
2020
Q4 | $1.05M | Hold |
38,685
| – | – | ﹤0.01% | 1962 |
|
|
2020
Q3 | $714K | Buy |
38,685
+4,970
| +15% | +$96.6K | ﹤0.01% | 1970 |
|
|
2020
Q2 | $688K | Buy |
33,715
+3,455
| +11% | +$55K | ﹤0.01% | 1971 |
|
|
2020
Q1 | $441K | Sell |
30,260
-943
| -3% | -$14.2K | ﹤0.01% | 2022 |
|
|
2019
Q4 | $443K | Buy |
31,203
+884
| +3% | +$11.3K | ﹤0.01% | 2279 |
|
|
2019
Q3 | $351K | Buy |
30,319
+15,721
| +108% | +$260K | ﹤0.01% | 2402 |
|
|
2019
Q2 | $293K | Sell |
14,598
-9,170
| -39% | -$181K | ﹤0.01% | 2422 |
|
|
2019
Q1 | $538K | Buy |
23,768
+14,598
| +159% | +$323K | ﹤0.01% | 2080 |
|
|
2018
Q4 | $208K | Sell |
9,170
-7,700
| -46% | -$192K | ﹤0.01% | 2381 |
|
|
2018
Q3 | $485K | Hold |
16,870
| – | – | ﹤0.01% | 2095 |
|
|
2018
Q2 | $460K | Buy |
16,870
+7,852
| +87% | +$209K | ﹤0.01% | 2135 |
|
|
2018
Q1 | $202K | Buy |
+9,018
| New | +$215K | ﹤0.01% | 2375 |
|
|
2016
Q4 | – | Sell |
-19,500
| Closed | -$436K | – | 2658 |
|
|
2016
Q3 | $436K | Hold |
19,500
| – | – | ﹤0.01% | 2057 |
|
|
2016
Q2 | $347K | Buy |
19,500
+8,100
| +71% | +$131K | ﹤0.01% | 2156 |
|
|
2016
Q1 | $156K | Sell |
11,400
-800
| -7% | -$12.1K | ﹤0.01% | 2496 |
|
|
2015
Q4 | $235K | Buy |
+12,200
| New | +$244K | ﹤0.01% | 2461 |
|
|
2015
Q3 | – | Sell |
-10,500
| Closed | -$348K | – | 2696 |
|
|
2015
Q2 | $348K | Buy |
+10,500
| New | +$288K | ﹤0.01% | 2269 |
|
Other funds holding TVTX
JT
PA
NAMI
UBS AM's TVTX Position: Q2 2026 in Review
UBS AM increased its Travere Therapeutics (TVTX) stake by 3.9% in Q2 2026, buying an estimated $237K and bringing the position to 142,368 shares worth $8.09M. The position accounts for ﹤0.01% of the portfolio, ranked #1368.
UBS AM first reported a position in TVTX in Q2 2015 and has held it in 39 quarters since. The position peaked at $8.25M in Q4 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.
- UBS AM held 142,368 shares of Travere Therapeutics worth $8.09M as of Q2 2026.
- UBS AM bought 5,343 Travere Therapeutics shares in Q2 2026, an estimated $237K.
- Travere Therapeutics made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1368 holding.
- UBS AM first reported a position in Travere Therapeutics in Q2 2015 and has held it in 39 quarters since.
- UBS AM's Travere Therapeutics position peaked at $8.25M in Q4 2025.
- 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.